(NASDAQ: ENTA) Enanta Pharmaceuticals's forecast annual revenue growth rate of 1.85% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 101.28%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.62%.
Enanta Pharmaceuticals's revenue in 2025 is $65,324,000.On average, 9 Wall Street analysts forecast ENTA's revenue for 2026 to be $1,904,152,376, with the lowest ENTA revenue forecast at $1,654,692,915, and the highest ENTA revenue forecast at $2,148,676,331. On average, 7 Wall Street analysts forecast ENTA's revenue for 2027 to be $1,907,760,201, with the lowest ENTA revenue forecast at $1,550,325,750, and the highest ENTA revenue forecast at $2,333,541,291.
In 2028, ENTA is forecast to generate $2,011,376,938 in revenue, with the lowest revenue forecast at $1,348,778,207 and the highest revenue forecast at $2,969,961,643.